Clinical Trial

pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer

Study acronym: RODEO
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
RODEO is a window of opportunity trial using dostarlimab in patients with newly diagnosed high-risk (stage 2-4) endometrial cancer who are suitable for primary surgery. Patients will receive 2 doses of dostarlimab (500mg IV day 1 and day 22) prior to surgery. The primary objective is to assess the pathological response rate to pre-operative dostarlimab and the secondary objectives are to assess the feasibility, toxicity, safety and efficacy of pre-operative dostarlimab.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-04.
Trial Details
NCT Number NCT07115927
Lead Sponsor University College, London
Collaborators: GlaxoSmithKline
Conditions Endometrial Cancer
Enrollment 40 participants
Start Date 2025-09-30
Primary Completion 2030-04-30 (estimated)
Study Completion 2031-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-19